H W Herr

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi request reprint Defining bacillus Calmette-Guerin refractory superficial bladder tumors
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Urol 169:1706-8. 2003
  2. ncbi request reprint Bladder cancer as a prognostic factor for upper tract transitional cell carcinoma
    Michael Mullerad
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 172:2177-81. 2004
  3. ncbi request reprint Defining optimal therapy for muscle invasive bladder cancer
    Harry W Herr
    Department of Urology and Genitourinary Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, Cornell University Weill Medical College, New York, New York 10021, USA
    J Urol 177:437-43. 2007
  4. doi request reprint Narrow-band imaging evaluation of bladder tumors
    Harry W Herr
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA
    Curr Urol Rep 15:395. 2014
  5. doi request reprint Should antibiotics be given prior to outpatient cystoscopy? A plea to urologists to practice antibiotic stewardship
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA Electronic address
    Eur Urol 65:839-42. 2014
  6. doi request reprint Outpatient urological procedures in antibiotic-naive patients with bladder cancer with asymptomatic bacteriuria
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    BJU Int 110:E658-60. 2012
  7. doi request reprint Intravesical bacille Calmette-Guérin eradicates bacteriuria in antibiotic-naïve bladder cancer patients
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Eur Urol 63:832-5. 2013
  8. doi request reprint Intravesical bacillus Calmette-Guérin outcomes in patients with bladder cancer and asymptomatic bacteriuria
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Urol 187:435-7. 2012
  9. ncbi request reprint Henry Wade (1876-1955): an early 20th century cancer researcher and pioneer urologist
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    BJU Int 98:514-8. 2006
  10. ncbi request reprint The enlarged prostate: a brief history of its surgical treatment
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, Cornell University Medical College, New York, NY 10021, USA
    BJU Int 98:947-52. 2006

Detail Information

Publications102 found, 100 shown here

  1. ncbi request reprint Defining bacillus Calmette-Guerin refractory superficial bladder tumors
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Urol 169:1706-8. 2003
    ..We define bacillus Calmette-Guerin (BCG) refractory, high risk, superficial bladder cancer...
  2. ncbi request reprint Bladder cancer as a prognostic factor for upper tract transitional cell carcinoma
    Michael Mullerad
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 172:2177-81. 2004
    ..Overall 5-year disease specific survival is in the range of 16.5% to 95% depending on stage. In this study we evaluated predictors associated with disease recurrence and disease specific survival...
  3. ncbi request reprint Defining optimal therapy for muscle invasive bladder cancer
    Harry W Herr
    Department of Urology and Genitourinary Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, Cornell University Weill Medical College, New York, New York 10021, USA
    J Urol 177:437-43. 2007
    ..We defined an optimal curative strategy for muscle invasive bladder cancer and to determine how best to deliver curative therapy...
  4. doi request reprint Narrow-band imaging evaluation of bladder tumors
    Harry W Herr
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA
    Curr Urol Rep 15:395. 2014
    ..Further prospective and comparative trials are required to determine whether NBI will play a role in evaluating and treating urothelial tumors in individual patients. ..
  5. doi request reprint Should antibiotics be given prior to outpatient cystoscopy? A plea to urologists to practice antibiotic stewardship
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA Electronic address
    Eur Urol 65:839-42. 2014
    ..Practice guidelines recommend that antibiotics be given before outpatient cystoscopy to prevent symptomatic urinary tract infection (UTI)...
  6. doi request reprint Outpatient urological procedures in antibiotic-naive patients with bladder cancer with asymptomatic bacteriuria
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    BJU Int 110:E658-60. 2012
    ..Pretreatment antibacterial therapy may not be necessary before outpatient urological procedures in patients with bladder cancer. Such strategy facilitates timely intervention and avoids antibiotic resistance...
  7. doi request reprint Intravesical bacille Calmette-Guérin eradicates bacteriuria in antibiotic-naïve bladder cancer patients
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Eur Urol 63:832-5. 2013
    ..BCG induces robust immune responses in the bladder that are responsible for its antitumor effect. We hypothesize that BCG-induced inflammation may eradicate bacterial infection...
  8. doi request reprint Intravesical bacillus Calmette-Guérin outcomes in patients with bladder cancer and asymptomatic bacteriuria
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Urol 187:435-7. 2012
    ..The outcome of intravesical bacillus Calmette-Guérin therapy was studied in patients with asymptomatic bacteriuria...
  9. ncbi request reprint Henry Wade (1876-1955): an early 20th century cancer researcher and pioneer urologist
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    BJU Int 98:514-8. 2006
  10. ncbi request reprint The enlarged prostate: a brief history of its surgical treatment
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, Cornell University Medical College, New York, NY 10021, USA
    BJU Int 98:947-52. 2006
  11. ncbi request reprint Can restaging transurethral resection of T1 bladder cancer select patients for immediate cystectomy?
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 177:75-9; discussion 79. 2007
    ..We determined whether pathological findings on restaging transurethral resection predict early stage progression of T1 bladder cancer...
  12. ncbi request reprint Ignorance is bliss: the Listerian revolution and education of American surgeons
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, Cornell University Medical College, New York, New York 10021, USA
    J Urol 177:457-60. 2007
    ..Joseph Lister introduced antiseptic surgery in 1867. American surgeons, entrenched in the old ways of 19th century medicine, failed to adopt Lister's methods...
  13. ncbi request reprint A re-staging transurethral resection predicts early progression of superficial bladder cancer
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    BJU Int 97:1194-8. 2006
    ..To determine whether pathology on a re-staging transurethral resection (TUR) predicts the early progression of superficial bladder cancer...
  14. ncbi request reprint Early history of endoscopic treatment of bladder tumors from Grunfeld's polypenkneipe to the Stern-McCarthy resectoscope
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Endourol 20:85-91. 2006
  15. ncbi request reprint Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Urol 174:2134-7. 2005
    ..This study was an evaluation of whether restaging transurethral resection (TUR) of superficial bladder cancer improves the early response to bacillus Calmette-Guerin (BCG) therapy...
  16. ncbi request reprint Urine cytology after flexible cystoscopy
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    BJU Int 96:796-7. 2005
    ..To correlate urine cytology findings before and after flexible cystoscopy...
  17. ncbi request reprint Franklin, Lavoisier, and Mesmer: origin of the controlled clinical trial
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Urol Oncol 23:346-51. 2005
    ..Using intentional subject ignorance and sham interventions to investigate mesmerism, Franklin's commission provided a model for the controlled clinical trial...
  18. ncbi request reprint Surgical factors in the treatment of superficial and invasive bladder cancer
    Harry W Herr
    Department of Urology, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Urol Clin North Am 32:157-64. 2005
    ..The challenge is how to get better at maximizing surgical efforts. The who and how of surgery in bladder cancer does indeed matter...
  19. ncbi request reprint Urethral injuries in the Civil War
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, Cornell University Medical College, New York, New York, USA
    J Urol 173:1090-3. 2005
    ..We compiled all cases of urethral injury received in battle during the Civil War to detail their management and determine the outcome of treatment...
  20. ncbi request reprint Legacy of Edwin Beer: fulguration of papillary bladder tumors
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Urol 173:1087-9. 2005
    ..Edwin Beer introduced the first endoscopic treatment of papillary bladder tumors in 1910. This historical review describes how his landmark discovery paved the way for office cystodiathermy to treat recurrent papillary tumors...
  21. ncbi request reprint Urachal carcinoma: contemporary surgical outcomes
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 178:74-8; discussion 78. 2007
    ..We determined surgical outcomes in a contemporary series of patients who underwent surgery for urachal carcinoma...
  22. ncbi request reprint Hunter Holmes McGuire and the coffee pot spout procedure
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, Cornell University Medical College, New York, New York 10021, USA
    J Urol 177:1250-3. 2007
    ..Hunter Holmes McGuire (1835 to 1900) was a Confederate surgeon who made a unique contribution to urology...
  23. ncbi request reprint The concept of lymph node density--is it ready for clinical practice?
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 177:1273-5; discussion 1275-6. 2007
    ..The concept of lymph node density (ratio of positive-to-total number of nodes examined) is reviewed as a prognostic factor for recurrence-free survival after cystectomy in patients with invasive bladder cancer...
  24. ncbi request reprint Age and outcome of superficial bladder cancer treated with bacille Calmette-Guérin therapy
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Urology 70:65-8. 2007
    ..To determine the influence of age on the outcomes of high-risk superficial bladder cancer treated with intravesical bacille Calmette-Guérin (BCG) therapy...
  25. doi request reprint Bacillus Calmette-Guérin without maintenance therapy for high-risk non-muscle-invasive bladder cancer
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Eur Urol 60:32-6. 2011
    ..Bacillus Calmette-Guérin (BCG) is the standard intravesical treatment of high-risk noninvasive (Ta, T1, Tis) bladder cancer. Maintenance BCG is recommended for maximum efficacy...
  26. doi request reprint Role of re-resection in non-muscle-invasive bladder cancer
    Harry W Herr
    Memorial Sloan Kettering Cancer Center, New York, USA
    ScientificWorldJournal 11:283-8. 2011
    ..Our conclusions show thatrestaging TUR improves the outcomes of high-risk,non-muscle-invasive bladder neoplasms...
  27. doi request reprint Reduced bladder tumour recurrence rate associated with narrow-band imaging surveillance cystoscopy
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    BJU Int 107:396-8. 2011
    ..To evaluate frequency of recurrences among patients with papillary bladder tumours followed sequentially with conventional white-light (WLI) cystoscopy and narrow-band imaging (NBI) cystoscopy...
  28. pmc Narrow-band imaging cystoscopy to evaluate bladder tumours--individual surgeon variability
    Harry Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    BJU Int 106:53-5. 2010
    ..Diagnosis (exploratory cohort) Level of Evidence 2b...
  29. doi request reprint Narrow-band imaging cystoscopy to evaluate the response to bacille Calmette-Guérin therapy: preliminary results
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    BJU Int 105:314-6. 2010
    ..Diagnostic (exploratory cohort)...
  30. doi request reprint Civiale, stones and statistics: the dawn of evidence-based medicine
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY 10021, USA
    BJU Int 104:300-2. 2009
    ..Civiale's insights and methods espoused similar concepts and ideas driving today's new paradigm of evidence-based medicine...
  31. doi request reprint Surgical management of renal tumors: a historical perspective
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, 1275 York Avenue, New York, NY 10021, USA
    Urol Clin North Am 35:543-9; v. 2008
    ..Surgery for kidney cancer continues to evolve. This article traces the history of surgical management for renal tumors...
  32. doi request reprint A comparison of white-light cystoscopy and narrow-band imaging cystoscopy to detect bladder tumour recurrences
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY 10021, USA
    BJU Int 102:1111-4. 2008
    ....
  33. doi request reprint 'I will not cut . . . ': the oath that defined urology
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA
    BJU Int 102:769-71. 2008
    ..To explore different interpretations of the clause embedded in the Hippocratic Oath, prohibiting surgery for stones, and its relevance for urology...
  34. doi request reprint 'Crushing the stone': a brief history of lithotripsy, the first minimally invasive surgery
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY 10021, USA
    BJU Int 102:432-5. 2008
    ..To trace the history of lithotripsy, marking the start of minimally invasive surgery...
  35. doi request reprint 'Cutting for the stone': the ancient art of lithotomy
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY 10021, USA
    BJU Int 101:1214-6. 2008
    ..Bladder stone was a common ailment plaguing mankind from antiquity to the 20th century. Largely forgotten today, lithotomy relieved the anguish of bladder stones and identified urology as a medical specialty nearly 2500 years ago...
  36. doi request reprint Outcome of patients who refuse cystectomy after receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, 1275 York Avenue, New York, NY 10021, USA
    Eur Urol 54:126-32. 2008
    ..To determine the outcome of patients who refuse cystectomy after receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer...
  37. ncbi request reprint History of bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 179:53-6. 2008
    ..We review how the bacillus Calmette-Guerin vaccine evolved to become standard therapy for superficial bladder cancer...
  38. ncbi request reprint Management of low grade papillary bladder tumors
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 178:1201-5; discussion 1205. 2007
    ..We evaluated the management and treatment outcomes of low grade papillary bladder tumors...
  39. ncbi request reprint A history of partial nephrectomy for renal tumors
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 173:705-8. 2005
    ..This article records the history of nephron sparing surgery for renal tumors...
  40. ncbi request reprint Urological injuries in the Civil War
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, Cornell University Medical College, New York, New York, USA
    J Urol 172:1800-4. 2004
    ..This study compiles all cases of urological injuries reported in the Civil War (1861 to 1865)...
  41. ncbi request reprint Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcome
    H W Herr
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 16:1298-301. 1998
    ....
  42. ncbi request reprint Paternity in men with stage I testis tumors on surveillance
    H W Herr
    Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 16:733-4. 1998
    ..We report long-term paternity in men with stage I testis tumors who were managed initially by surveillance...
  43. ncbi request reprint Standardization of radical cystectomy: time to count and be counted
    Harry W Herr
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    BJU Int 94:481-2. 2004
  44. doi request reprint Bladder cancer in cystoscopically normal-appearing mucosa: a case of mistaken identity?
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    BJU Int 106:1499-501. 2010
    ....
  45. ncbi request reprint Pathologic evaluation of radical cystectomy specimens: a cooperative group report
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 100:2470-5. 2004
    ..Their objective was to determine whether current practices conform to suggested pathology practice guidelines for reporting on radical cystectomy and pelvic lymph node specimens...
  46. ncbi request reprint Transurethral resection of muscle-invasive bladder cancer: 10-year outcome
    H W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 19:89-93. 2001
    ..To determine the 10-year outcome of patients with muscle-invasive bladder cancer treated by transurethral resection (TUR) alone...
  47. ncbi request reprint Low-volume nodal metastases detected at retroperitoneal lymphadenectomy for testicular cancer: pattern and prognostic factors for relapse
    F Rabbani
    Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 19:2020-5. 2001
    ..In contrast, patients with elevated markers before retroperitoneal lymphadenectomy have a high rate of relapse and should be considered for primary chemotherapy...
  48. ncbi request reprint The efficacy of transurethral biopsy for predicting the long-term clinical impact of prostatic invasive bladder cancer
    S M Donat
    Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA
    J Urol 165:1580-4. 2001
    ..However, it did not have significant clinical impact or affect survival and should not be an absolute contraindication to urethral diversion...
  49. pmc A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience
    Atreya Dash
    Division of Urology, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 113:2471-7. 2008
    ..Gemcitabine plus cisplatin (GC) has similar efficacy and less toxicity than MVAC in metastatic disease, but is untested as neoadjuvant treatment...
  50. ncbi request reprint Partial cystectomy: a contemporary review of the Memorial Sloan-Kettering Cancer Center experience and recommendations for patient selection
    Jeffrey M Holzbeierlein
    Department of Urology, Memorial Sloan Kettering Cancer Center, 353 E 68th Street, New York, NY 10021, USA
    J Urol 172:878-81. 2004
    ..This study analyzes the outcomes of partial cystectomy in a contemporary cohort of patients to identify appropriate selection criteria for the procedure...
  51. ncbi request reprint Surgical factors influence bladder cancer outcomes: a cooperative group report
    Harry W Herr
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 22:2781-9. 2004
    ..We evaluated whether surgical factors from patients enrolled onto the study predicted bladder cancer outcomes...
  52. ncbi request reprint Does early cystectomy improve the survival of patients with high risk superficial bladder tumors?
    H W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Urol 166:1296-9. 2001
    ..We compared survival after early versus delayed cystectomy in patients with high risk superficial bladder tumors...
  53. doi request reprint Impact of previous radiotherapy for prostate cancer on clinical outcomes of patients with bladder cancer
    David S Yee
    Urology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Urol 183:1751-6. 2010
    ..We compared the outcomes of patients with bladder cancer previously treated for prostate cancer with radiotherapy vs other treatment modalities...
  54. ncbi request reprint Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer
    Harry W Herr
    Departments of Urology Genitourinary Oncology Service, Medicine and Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Urol 167:1295-8. 2002
    ..We postulate that the number of lymph nodes examined in cystectomy specimens can have an impact on the outcome of patients with bladder cancer...
  55. ncbi request reprint Extent of surgery and pathology evaluation has an impact on bladder cancer outcomes after radical cystectomy
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Urology 61:105-8. 2003
    ..To evaluate whether the extent of surgery and of the pathology evaluation affects the outcome of patients with bladder cancer after radical cystectomy...
  56. ncbi request reprint Positive surgical margins in soft tissue following radical cystectomy for bladder cancer and cancer specific survival
    Zohar A Dotan
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 178:2308-12; discussion 2313. 2007
    ..We evaluated risk factors for positive soft tissue surgical margins and the impact of soft tissue surgical margins on metastatic progression and disease specific survival in patients treated with radical cystectomy for bladder cancer...
  57. ncbi request reprint Mechanisms of prostatic stromal invasion in patients with bladder cancer: clinical significance
    S M Donat
    Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA
    J Urol 165:1117-20. 2001
    ..Such direct silent tumor invasion of the prostate by superficial or endoscopically inapparent tumor is difficult to detect clinically by current biopsy methods. New methods of detection are necessary...
  58. ncbi request reprint Upper-tract tumors after an initial diagnosis of bladder cancer: argument for long-term surveillance
    F Rabbani
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 19:94-100. 2001
    ....
  59. doi request reprint Accuracy of the extent of bladder cancer nodal metastases found at pelvic lymphadenectomy at the time of cystectomy: relation to primary tumor stage
    Farhang Rabbani
    Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue New York, NY 10021, USA
    Urol Int 84:14-22. 2010
    ....
  60. ncbi request reprint Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract
    Matthew D Galsky
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Urology 69:255-9. 2007
    ..A unifying feature of these malignancies is their aggressive course and poor outcome with standard chemotherapeutic regimens. Given the rarity of these tumors, no prospective data are available to guide management...
  61. doi request reprint Clinical outcomes of primary bladder carcinoma in situ in a contemporary series
    Daher C Chade
    Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Urol 184:74-80. 2010
    ..We describe patterns of disease recurrence and progression, and identify clinical outcome predictors of primary carcinoma in situ after bacillus Calmette-Guerin therapy...
  62. ncbi request reprint Superiority of ratio based lymph node staging for bladder cancer
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Urol 169:943-5. 2003
    ..The current study evaluated lymph node staging and the outcome in patients with lymph node positive bladder cancer after radical cystectomy...
  63. ncbi request reprint Post-chemotherapy surgery in patients with unresectable or regionally metastatic bladder cancer
    H W Herr
    Department of Urology and Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center, Weill Medical College, Cornell University, New York, New York, USA
    J Urol 165:811-4. 2001
    ..Optimal candidates include those in whom the pre-chemotherapy sites of disease are restricted to the bladder and pelvis or regional lymph nodes, and who have a major response to chemotherapy...
  64. ncbi request reprint Outpatient flexible cystoscopy in men: a randomized study of patient tolerance
    H W Herr
    Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA
    J Urol 165:1971-2. 2001
    ..1 after immediate cystoscopy versus 1.8 after delayed cystoscopy (p = 0.7). CONCLUSIONS: There was no difference in pain perception in men undergoing immediate or delayed outpatient flexible cystoscopy using the same local anesthetic...
  65. ncbi request reprint Value of urethral wash cytology in the retained male urethra after radical cystoprostatectomy
    Daniel W Lin
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 169:961-3. 2003
    ..We retrospectively evaluated the outcome in post-cystectomy urethrectomy cases at our institution from 1994 to 2000...
  66. ncbi request reprint Impact of separate versus en bloc pelvic lymph node dissection on the number of lymph nodes retrieved in cystectomy specimens
    B H Bochner
    Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA
    J Urol 166:2295-6. 2001
    ..Such information is important for identifying patients who may benefit from adjuvant chemotherapy...
  67. ncbi request reprint Results of high dose rate brachytherapy, anterior pelvic exenteration and external beam radiotherapy for carcinoma of the female urethra
    G Dalbagni
    Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    J Urol 166:1759-61. 2001
    ..Local control seems to have improved. We must evaluate a larger cohort of patients to determine this impact of the combined modality on local control and patient survival...
  68. ncbi request reprint Surgical factors in bladder cancer: more (nodes) + more (pathology) = less (mortality)
    H W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    BJU Int 92:187-8. 2003
  69. doi request reprint Urachal carcinoma: a clinicopathologic analysis of 24 cases with outcome correlation
    Anuradha Gopalan
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Am J Surg Pathol 33:659-68. 2009
    ..Detailed pathologic studies with clinical outcome correlation are few...
  70. doi request reprint Clinical outcome in a contemporary series of restaged patients with clinical T1 bladder cancer
    Guido Dalbagni
    Division of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Eur Urol 56:903-10. 2009
    ..To evaluate the indications for early and deferred cystectomy and to report the impact of this tailored approach on survival...
  71. doi request reprint Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience
    S Machele Donat
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, United States
    Eur Urol 55:177-85. 2009
    ..However, in a recent report from the National Cancer Database (NCDB), only 11.6% of stage III BCa patients received perioperative chemotherapy, the majority in the adjuvant setting...
  72. doi request reprint Radical cystectomy in octogenarians--does morbidity outweigh the potential survival benefits?
    S Machele Donat
    Department of Urology, the Genitourinary Oncology Service in the Department of Medicine MIM, and the Department of Epidemiology and Biostatistics AC, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Urol 183:2171-7. 2010
    ..4% of those with similar stage disease age 65 to 79 years, reflecting concern for perioperative morbidity. We evaluated the morbidity and survival outcomes of octogenarians treated with radical cystectomy at a tertiary cancer center...
  73. doi request reprint Clinical outcome of primary versus secondary bladder carcinoma in situ
    Daher C Chade
    Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Urol 184:464-9. 2010
    ..Differences in clinical outcome are still unclear between primary and secondary bladder carcinoma in situ. We compared the clinical outcomes of primary and secondary carcinoma in situ, and identified predictive factors...
  74. doi request reprint Age-adjusted Charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancer
    Theresa M Koppie
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer 112:2384-92. 2008
    ..Also evaluated was whether ACCI was associated with clinicopathologic and treatment characteristics...
  75. ncbi request reprint Prospective evaluation of p53 as a prognostic marker in T1 transitional cell carcinoma of the bladder
    Guido Dalbagni
    Department of Urology, Division of Epidemiology and Biostatistics, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    BJU Int 99:281-5. 2007
    ....
  76. ncbi request reprint Max Nitze, the cystoscope and urology
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Urol 176:1313-6. 2006
    ..Maximilian Carl-Friedrich Nitze (1848 to 1906) designed the modern cystoscope, providing a foundation for urology...
  77. ncbi request reprint Phase II trial of intravesical gemcitabine in bacille Calmette-Guérin-refractory transitional cell carcinoma of the bladder
    Guido Dalbagni
    Department of Urology, Division of Epidemiology and Biostatistics, The Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 24:2729-34. 2006
    ..The aim of this phase II study was to determine the efficacy of gemcitabine administered as an intravesical agent in patients with bacille Calmette-Guérin (BCG) -refractory transitional cell carcinoma of the bladder...
  78. ncbi request reprint Clinical characteristics of bladder cancer in patients previously treated with radiation for prostate cancer
    Jaspreet S Sandhu
    Department of Urology, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY, USA
    BJU Int 98:59-62. 2006
    ....
  79. ncbi request reprint Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin-refractory transitional-cell carcinoma of the bladder
    Guido Dalbagni
    Department of Urology, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Clin Oncol 20:3193-8. 2002
    ..The aim of this phase I study was to determine the safety and toxicity profile of gemcitabine administered as an intravesical agent in patients with transitional-cell carcinoma (TCC) of the bladder...
  80. ncbi request reprint Efficacy of office fulguration for recurrent low grade papillary bladder tumors less than 0.5 cm
    S Machele Donat
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 171:636-9. 2004
    ..We report our experience with office fulguration of small, recurrent, low grade papillary tumors using flexible cystodiathermy...
  81. ncbi request reprint Prospectively packaged lymph node dissections with radical cystectomy: evaluation of node count variability and node mapping
    Bernard H Bochner
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 172:1286-90. 2004
    ..We prospectively evaluated RC cases with transitional cell carcinoma of the bladder to determine which factors may contribute to the variability in the number of reported LNs...
  82. ncbi request reprint Fluid intake and the risk of tumor recurrence in patients with superficial bladder cancer
    S Machele Donat
    Department of Urology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Urol 170:1777-80. 2003
    ..High fluid intake has been associated with a decreased risk of bladder cancer development in men. We evaluated whether higher fluid intake can impact tumor recurrence rates in patients with superficial bladder cancer...
  83. ncbi request reprint Temporal change in risk of metachronous contralateral renal cell carcinoma: influence of tumor characteristics and demographic factors
    Farhang Rabbani
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 20:2370-5. 2002
    ....
  84. doi request reprint Radical cystectomy and orthotopic urinary reconstruction in patients with bladder cancer after renal transplantation: clinical outcomes and description of technique
    K A Moses
    Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Transplant Proc 45:1661-6. 2013
    ..In the setting of prior renal transplantation, surgical treatment remains the mainstay but is technically challenging. We report our patient outcomes in this unique population with a description of the technique...
  85. ncbi request reprint Does cystoscopy correlate with the histology of recurrent papillary tumours of the bladder?
    H W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    BJU Int 88:683-5. 2001
    ....
  86. ncbi request reprint Safety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patients
    Ofer Yossepowitch
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 176:482-5. 2006
    ..We assessed the safety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patients...
  87. ncbi request reprint Impact of a second transurethral resection on the staging of T1 bladder cancer
    Guido Dalbagni
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Urology 60:822-4; discussion 824-5. 2002
    ..To evaluate the impact of a second transurethral resection (TUR) on the pathologic stage in a unique patient population with T1 tumors...
  88. ncbi request reprint Radiographic versus pathologic size of renal tumors: implications for partial nephrectomy
    H W Herr
    Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA
    Urology 58:157-60. 2001
    ....
  89. ncbi request reprint A comparison of hospital-based charges following partial and radical nephrectomy
    J M McKiernan
    Department of Urology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, C 1064, New York, NY 10021, USA
    Urol Oncol 7:3-6. 2002
    ..We retrospectively compared the hospital based charges for these two procedures in a similar cohort of patients treated at Memorial Sloan-Kettering Cancer Center...
  90. ncbi request reprint Immediate versus delayed outpatient flexible cystoscopy: final report of a randomized study
    H W Herr
    Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA
    Can J Urol 8:1406-8. 2001
    ..8 after immediate cystoscopy versus 1.7 after delayed cystoscopy (p=5). CONCLUSION: There was no difference in pain perception among men undergoing an immediate or a delayed outpatient flexible cystoscopy using the same local anesthetic...
  91. ncbi request reprint Orthotopic urinary diversion after cystectomy for bladder cancer: implications for cancer control and patterns of disease recurrence
    Ofer Yossepowitch
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Urol 169:177-81. 2003
    ..The impact of orthotopic urinary diversion on the quality of cystectomy and ensuing cancer control has not been adequately studied. We analyzed our experience with this clinical problem...
  92. pmc Positive surgical margins at partial nephrectomy: predictors and oncological outcomes
    Ofer Yossepowitch
    Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 179:2158-63. 2008
    ..We combine data from 2 tertiary care intuitions, and report predictors of positive surgical margins and long-term oncological outcomes for patients with positive surgical margins...
  93. ncbi request reprint Feasibility of radical prostatectomy after neoadjuvant chemohormonal therapy for patients with high risk or locally advanced prostate cancer: results of a phase I/II study
    Badrinath R Konety
    Department of Urology, Memorial Sloan Kettering Cancer Center and Cornell University, New York, New York 10021, USA
    J Urol 171:709-13. 2004
    ....
  94. doi request reprint Rebuttal from author re: Axel Heidenreich. Muscle-invasive urothelial carcinoma of the bladder: neoadjuvant chemotherapy enables organ preserving therapy in carefully selected patients. Eur Urol 2008;54:21-23
    Harry W Herr
    Eur Urol 54:23-4. 2008
  95. ncbi request reprint Correlation of cystoscopy with histology of recurrent papillary tumors of the bladder
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Urol 168:978-80. 2002
    ....
  96. doi request reprint Lymph node density is superior to TNM nodal status in predicting disease-specific survival after radical cystectomy for bladder cancer: analysis of pooled data from MDACC and MSKCC
    Wassim Kassouf
    Department of Urology and the Division of Quantitative Sciences, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 26:121-6. 2008
    ..To compare the utility of lymph node density (LND) with TNM nodal status in predicting disease-specific survival (DSS) after radical cystectomy...
  97. ncbi request reprint Bladder cancer. Clinical guidelines in oncology
    James E Montie
    J Natl Compr Canc Netw 4:984-1014. 2006
  98. ncbi request reprint Low risk bladder tumors--less is more!
    Harry W Herr
    J Urol 179:13-4. 2008
  99. ncbi request reprint Use of urinary biomarkers for bladder cancer surveillance: patient perspectives
    Ofer Yossepowitch
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 177:1277-82; discussion 1282. 2007
    ..We assessed whether patients would accept a urine biomarker assay over flexible cystoscopy for monitoring bladder cancer...
  100. ncbi request reprint Pathologic evaluation of radical cystectomy specimens
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer 95:668-9. 2002
  101. ncbi request reprint Is less radical cystectomy better, and how can we be sure?
    Harry W Herr
    J Urol 173:1063. 2005